Emergent BioSolutions
EBS
$5.36
Share price
23.22%
Change (1 day)
-42.30%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - P/B ratio
P/B ratio as of May 2024 : 0.4326
According to Emergent BioSolutions
's latest financial reports the company has a price-to-book ratio of 0.4326.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Emergent BioSolutions - P/B ratio (from 2006 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 0.1918 | -54.83% |
| 2022-12-31 | 0.4246 | -70.74% |
| 2021-12-31 | 1.45 | -55.78% |
| 2020-12-31 | 3.28 | 28.07% |
| 2019-12-31 | 2.56 | -14.65% |
| 2018-12-31 | 3.00 | 18.13% |
| 2017-12-31 | 2.54 | 13.93% |
| 2016-12-31 | 2.23 | -6.62% |
| 2015-12-31 | 2.39 | 28.7% |
| 2014-12-31 | 1.86 | 7.84% |
| 2013-12-31 | 1.72 | 32.27% |
| 2012-12-31 | 1.30 | -10.43% |
| 2011-12-31 | 1.45 | -33.92% |
| 2010-12-31 | 2.20 | 27.95% |
| 2009-12-31 | 1.72 | -56.15% |
| 2008-12-31 | 3.92 | 345.58% |
| 2007-12-31 | 0.8795 | -60.46% |
| 2006-12-31 | 2.22 | |
| 2005-12-31 | N/A | |
| 2004-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.80 | 317.25% | 🇺🇸 USA |
 Merck MRK | 8.70 | 1,911.45% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.53 | 1,177.68% | 🇬🇧 UK |
 Soligenix SNGX | 2.20 | 409.03% | 🇺🇸 USA |
 SIGA Technologies SIGA | 2.69 | 522.22% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 6.16 | 1,324.00% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 2.35 | 443.90% | 🇮🇱 Israel |